High lipoprotein(a): meaning and who should test

What is lipoprotein(a), and why does it matter?

Lipoprotein(a), or Lp(a), is an LDL-like particle consisting of an apolipoprotein B-100-containing particle linked to apolipoprotein(a). Its structure helps explain its atherogenic and inflammatory effects and its association with atherosclerotic cardiovascular disease and calcific aortic valve stenosis^1,2. Much of the variation in Lp(a) concentration among individuals is explained by genetic factors, particularly variants in the LPA gene, which helps explain why high levels and premature cardiovascular events may cluster in some families^3,1. Diet, exercise, and weight loss have little direct effect on Lp(a), although they remain important for lowering overall cardiovascular risk^3,1,4. High Lp(a) usually causes no symptoms and can only be identified through a specific blood test, which may not be included in a standard lipid panel⁴.

Who should have Lp(a) measured?

Measuring Lp(a) at least once in adulthood, when testing is available, is supported by European guidance, the 2024 National Lipid Association update, and the American Heart Association scientific statement^5,3,1. At the update date of this content, the officially published US guideline was the 2018 AHA/ACC multisociety guideline, published in 2019; it considers elevated Lp(a) a risk-enhancing factor in selected situations. Testing is also particularly relevant after premature or otherwise unexplained myocardial infarction, stroke, or peripheral artery disease; with a family history of premature cardiovascular disease or high Lp(a); in familial hypercholesterolemia; with aortic stenosis, particularly at an early age; after recurrent events despite controlled LDL cholesterol; or when estimated risk is close to a threshold for starting or intensifying treatment^5,3,1,2,6. The documents do not use entirely identical terminology and thresholds, and the frequency of results classified as elevated varies with population, ancestry, laboratory method, and cutoff^3,6,4. In families affected by premature cardiovascular disease or high Lp(a), testing first-degree relatives—including parents, siblings, and children—may be discussed, particularly when the initial case has a clinically relevant concentration^5,1,6.

How is Lp(a) tested, and why do the units matter?

Lp(a) is measured from a blood sample and does not require fasting specifically for this test. Fasting may still be requested because of other tests collected at the same time¹. The preferred method is an assay minimally affected by apolipoprotein(a) isoform size, calibrated against reference material and ideally reported as particle concentration in nmol/L; results in mg/dL can also be used when this is the unit validated by the laboratory^5,3,1. A fixed formula should not be used to convert mg/dL into nmol/L because particle mass varies with apolipoprotein(a) size^5,3,1. For pragmatic interpretation, the 2024 NLA update considers values below 30 mg/dL or 75 nmol/L to represent lower Lp(a)-related risk, 30–49 mg/dL or 75–124 nmol/L an intermediate range, and at least 50 mg/dL or 125 nmol/L an elevated range; AHA documents and the published AHA/ACC guideline also recognize 50 mg/dL or 125 nmol/L as a clinically relevant threshold^3,1,6. These paired ranges are not mathematical conversions, so the result should be interpreted in the unit reported by the laboratory.

What does a high result mean for cardiovascular risk?

High Lp(a) is a cardiovascular risk modifier, not a stand-alone prediction that someone will have a heart attack. Epidemiological, genetic, and Mendelian randomization studies support a causal, continuous, and independent association between increasing Lp(a) concentrations and atherosclerotic cardiovascular disease, with particularly strong associations for myocardial infarction and aortic stenosis, as well as links to peripheral artery disease, ischemic stroke, and recurrent cardiovascular events^5,3,1,2. There is no abrupt biological boundary between normal and abnormal, so a mild elevation should not be interpreted in the same way as an extreme elevation^3,1,2. Concentrations of at least 50 mg/dL or 125 nmol/L are often regarded as clinically elevated, but risk rises continuously, and this threshold is neither a stand-alone diagnosis nor a measure of an individual's probability of an event^1,4. European guidance regards concentrations above 180 mg/dL as an extreme elevation potentially associated with lifetime risk similar to that of heterozygous familial hypercholesterolemia, while recognizing that lower levels can still modify risk⁵. These relative risks are not an individual's probability of having a heart attack. In the population model presented by the EAS consensus, for example, 30 mg/dL increased estimated lifetime risk from 5% to 6.1% in a person with low baseline risk and from 25% to 30.5% in someone with higher baseline risk; at 75 mg/dL, the estimated absolute increases were 3.3 and 16.3 percentage points, respectively². In clinical practice, Lp(a) should be interpreted alongside age, sex, blood pressure, smoking, diabetes, LDL cholesterol, non-HDL cholesterol, apolipoprotein B when indicated, kidney function, family history, established cardiovascular disease, aortic stenosis, and evidence of subclinical atherosclerosis when imaging is otherwise appropriate^5,3,1,2. Average Lp(a) concentrations tend to be higher in people of African or South Asian ancestry, but a result should not be dismissed or mathematically adjusted solely because of ancestry or self-identified race^3,1,2,4.

What can be done when Lp(a) is elevated?

Current management focuses on consistently reducing every modifiable risk factor according to the person's overall cardiovascular risk. This includes controlling LDL cholesterol and other atherogenic particles, blood pressure, and diabetes; stopping smoking; staying physically active; and addressing inactivity and excess weight^5,3,1,2,4. Statins and ezetimibe do not significantly lower Lp(a), but they remain appropriate when needed to reduce LDL cholesterol and cardiovascular events; high Lp(a) is not a reason to stop an otherwise appropriately indicated statin^5,3,1. PCSK9 inhibitors may lower Lp(a) by approximately 20% to 30%, but they are prescribed mainly according to LDL cholesterol and overall-risk indications rather than as universal treatment for isolated Lp(a) elevation^5,3,1. In a ClinicalTrials.gov search conducted on June 24, 2025, the Lp(a)HORIZON outcomes trial remained registered without cardiovascular endpoint results posted in the registry. A peer-reviewed phase 2 trial showed that pelacarsen lowers Lp(a) concentration, but it was not designed to establish a reduction in cardiovascular events. These data therefore should not prompt changes in clinical management or routine use of the drug before complete evaluation of the outcomes trial and publication of peer-reviewed scientific results^7,8.

What are the most common questions about Lp(a)?

Lp(a) can remain clinically relevant even when LDL cholesterol is low or at its treatment target. It may help explain premature cardiovascular disease, recurrent events, or part of the residual risk, although it is not the only possible explanation^5,3,1,2. Does the test need to be repeated? One measurement correctly classifies most adults because Lp(a) is usually stable throughout life; repeat testing may be considered during or after the menopausal transition, pregnancy, kidney, liver, or thyroid disease, exposure to certain medications, or when a result is unexpected^3,1. Can diet and exercise normalize Lp(a)? They usually have little direct effect on its concentration, but they remain essential because they lower other components of cardiovascular risk^3,1,4. Does high Lp(a) mean a heart attack is inevitable? No. The result modifies risk and must be combined with personal history, family history, and other clinical factors.

When should you seek an individual cardiovascular assessment?

Content updated on June 24, 2025. Consider a cardiovascular assessment to discuss testing or interpret a result, particularly if you have premature cardiovascular disease, recurrent events, aortic stenosis, familial hypercholesterolemia, high Lp(a) in the family, or uncertainty about starting or intensifying prevention. An individual consultation can confirm the laboratory method and unit, estimate overall cardiovascular risk, and establish goals and management proportionate to the clinical profile. References:⁵ Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188. DOI: https://doi.org/10.1093/eurheartj/ehz455. Accessed June 24, 2025.³ Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 National Lipid Association scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology. 2024;18(3):e308-e319. DOI: https://doi.org/10.1016/j.jacl.2024.03.001. Accessed June 24, 2025.¹ Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-e60. DOI: https://doi.org/10.1161/ATV.0000000000000147. Accessed June 24, 2025.² Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925-3946. DOI: https://doi.org/10.1093/eurheartj/ehac361. Accessed June 24, 2025.⁶ Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. DOI: https://doi.org/10.1161/CIR.0000000000000625. Accessed June 24, 2025.⁴ Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology. 2017;69(6):692-711. DOI: https://doi.org/10.1016/j.jacc.2016.11.042. Accessed June 24, 2025.⁷ Novartis Pharmaceuticals. Assessing the Impact of Lipoprotein(a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD — Lp(a)HORIZON. ClinicalTrials.gov, record NCT04023552, 2019. Source type: official clinical trial registry. URL: https://clinicaltrials.gov/study/NCT04023552. Accessed June 24, 2025.⁸ Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine. 2020;382:244-255. DOI: https://doi.org/10.1056/NEJMoa1905239. Accessed June 24, 2025. This content is for informational and educational purposes only and does not replace individual medical consultation, diagnosis, or treatment.